Drugs / LY2881835
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01358981 | May → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2881835 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01358981 ↗ |
| Action | Activate | “Free fatty acid receptor 1 agonist” CHEMBL3915620 ↗ |
| Modality | Small molecule | — CHEMBL3915620 ↗ |
| Route | Oral | “Administered orally” NCT01358981 ↗ |
| Target | FFAR1 | “Free fatty acid receptor 1 agonist” CHEMBL3915620 ↗ |